样式: 排序: IF: - GO 导出 标记为已读
-
Effect of Chemotherapy and Surgery Timing on Mortality in Upper and Lower Extremity Osteosarcoma J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-20 Mark D Danese, John S Groundland
Background Surgery with both neoadjuvant and adjuvant chemotherapy represents the standard of care for extremity osteosarcoma despite a lack of high-quality evidence for its use, and trial evidence that suggests that up-front surgery may result in better outcomes. This study estimated the difference in overall survival for the standard of care (“Neoadjuvant First”) vs upfront surgery first followed
-
Strength of Evidence Underlying the CMS-FDA Parallel Review of Comprehensive Genomic Profiling Tests in the Cancer Setting J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-18 Sydnie Stackland, Dominic Schnabel, Michaela Dinan, Carolyn J Presley, Cary P Gross
Background Although use of comprehensive genomic profiling (CGP) was approved by a novel CMS/FDA parallel review process, the quality of the supporting evidence is unclear. We evaluated the rigor of the peer-reviewed literature cited in the National Coverage Determination Memorandum for the FoundationOne CDx (F1CDx). Methods We identified studies cited in the memorandum. Two independent researchers
-
Benefits and Harms of Hepatocellular Carcinoma Screening Outreach in Patients with Cirrhosis: A Multi-Center Randomized Clinical Trial J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-17 Amit G Singal, Darine Daher, Manasa Narasimman, Sruthi Yekkaluri MHI, Yan Liu, Vanessa Cerda, Chaitra Banala, Aisha Khan, MinJae Lee, Karim Seif El Dahan, Caitlin C Murphy, Jennifer R Kramer, Ruben Hernaez
Background The value of hepatocellular carcinoma (HCC) screening is defined by the balance of benefits from early tumor detection vs harms due to false positive results. We evaluated the value of a mailed outreach strategy for HCC screening in patients with cirrhosis. Methods We conducted a multi-center pragmatic randomized clinical trial comparing mailed outreach for HCC screening (n = 1436) and usual
-
County-level jail and state-level prison incarceration and cancer mortality in the United States J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-17 Jingxuan Zhao, Sandhya Kajeepeta, Christopher R Manz, Xuesong Han, Leticia M Nogueira, Zhiyuan Zheng, Qinjin Fan, Kewei Sylvia Shi, Fumiko Chino, K Robin Yabroff
This study examined the association of county-level jail and state-level prison incarceration rates and cancer mortality rates in the United States. Incarceration rates (1995-2018) were sourced from national data and categorized into quartiles. County- and state-level mortality rates (2000-2019) with invasive cancer as the underlying cause of death were obtained from the National Vital Statistics System
-
Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-14 Jianhui Zhao, Erxu Xue, Siyun Zhou, Meng Zhang, Jing Sun, Yuqian Tan, Xue Li
Background Allostatic load (AL) reflects the cumulative burden of chronic stress throughout life, potentially influencing the onset and prognosis of cancer. However, the associations between AL, colorectal cancer (CRC) risk and all-cause mortality in patients with CRC remain unclear. Methods We analyzed the association between AL and CRC risk in 304,959 adults and all-cause mortality in 1,794 patients
-
Histopathological response to chemotherapy and survival of mucinous type gastric cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-14 Irene A Caspers, Astrid E Slagter, Pauline A J Vissers, Martha Lopez-Yurda, Laurens V Beerepoot, Jelle P Ruurda, Grard A P Nieuwenhuijzen, Suzanne S Gisbertz, Mark I Van Berge Henegouwen, Henk H Hartgrink, Danny Goudkade, Liudmila L Kodach, Johanna W Van Sandick, Marcel Verheij, Rob H A Verhoeven, Annemieke Cats, Nicole C T Van Grieken
Background Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC) and diffuse (dif-GC) gastric cancer. Methods Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy
-
Health Insurance Continuity and Mortality in Children and Adolescents/Young Adults with Blood Cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-13 Xu Ji, Xinyue (Elyse) Zhang, K Robin Yabroff, Wendy Stock, Patricia Cornwell, Shasha Bai, Ann C Mertens, Joseph Lipscomb, Sharon M Castellino
Background Many uninsured patients do not receive Medicaid coverage until a cancer diagnosis, potentially delaying access to care for early cancer detection and treatment. We examine the association of Medicaid enrollment timing and patterns with survival among children and adolescents/young adults (AYAs) diagnosed with blood cancers, where disease onset can be acute and early detection is critical
-
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-13 Hormuzd A Katki, Philip C Prorok, Philip E Castle, Lori M Minasian, Paul F Pinsky
Background Cancer screening trials have required large sample sizes and long time-horizons to demonstrate cancer mortality reductions, the primary goal of cancer screening. We examine assumptions and potential power gains from exploiting information from testing control-arm specimens, which we call the “intended effect” (IE) analysis that we explain in detail herein. The IE analysis is particularly
-
-
NCCN guideline-concordant cancer care in Sub-Saharan Africa A population-based multi-country study of five cancers. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-12 Nikolaus Christian Simon Mezger,Tobias Paul Seraphin,Robert Ballé,Mirko Griesel,Yvonne Walburga Joko-Fru,Lucia Hämmerl,Jana Feuchtner,Biying Liu,Annelle Zietsman,Bakarou Kamaté,Freddy Houéhanou Rodrigue Gnangnon,Franck Gnahatin,Dimitry Moudiongui Mboungou,Mathewos Assefa,Phoebe Mary Amulen,Gladys Chesumbai,Tatenda Chingonzoh,Cesaltina Feirreira Lorenzoni,Anne Korir,Pablo S Carvalho Santos,Jörg Michael
BACKGROUND To assess population-based quality of cancer care in Sub-Saharan Africa and to identify specific gaps and joint opportunities, we assessed concordance of diagnostic and treatment with NCCN harmonized guidelines for leading cancer types in 10 countries. METHODS Adult patients with female breast cancer (BC), cervical cancer (CC), colorectal cancer (CRC), Non-Hodgkin lymphoma (NHL) and prostate
-
Quality-of-Life Outcomes from NRG/NSABP B-39/RTOG 0413: Whole-breast Irradiation vs Accelerated Partial-breast Irradiation after Breast Conserving Surgery J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-10 Patricia A Ganz, Reena S Cecchini, Julia R White, Frank A Vicini, Douglas W Arthur, Rachel A Rabinovitch, Robert R Kuske, Thomas B Julian, David S Parda, Michael F Scheier, Kathryn A Winter, Soonmyung Paik, Henry M Kuerer, Laura A Vallow, Lori J Pierce, Eleftherios P Mamounas, Beryl McCormick, Harry D Bear, Isabelle Germain, Gregory S Gustafson, Linda Grossheim, Ivy A Petersen, Richard S Hudes, Walter
PURPOSE NRG Oncology (NRG)/NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was Quality-of-life (QOL). METHODS The QOL sub-study used validated self-report questionnaires including the Breast Cancer Treatment Outcome Scale (BCTOS) and SF-36 vitality scale. Assessments
-
The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-09 Michelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, Thuy T Koll, Christina K Cramer, Glenn J Lesser, Debra L Barton, Karen M Mustian, Lynne I Wagner, Patricia A Ganz, Peter D Cole, Alexis Bakos, James C Root, Kristina Hardy, Allison Magnuson, Robert J Ferguson, Brenna C McDonald, Andrew J Saykin, Brian D Gonzalez, Jeffrey S Wefel, David A Morilak, Saurabh Dahiya, Cobi J Heijnen, Yvette P Conley
Cancer-related cognitive impairment (CRCI) is a broad term encompassing subtle cognitive problems to more severe impairment. CRCI severity is influenced by host, disease, and treatment factors and affects patients prior to, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a Clinical
-
Lower survival for surgical treatment of HPV-related oropharynx cancer at community cancer centers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-09 Danielle R Trakimas, Wojciech K Mydlarz, Leila J Mady, Christine G Gourin, Wayne Koch, Nyall R London, Harry Quon, Ana P Kiess, Tanguy Y Seiwert, Carole Fakhry
Background The rate of primary surgery for human papillomavirus-related oropharynx cancer (HPVOPC) has recently declined, while utilization of transoral robotic surgery (TORS) has lagged at community cancer centers (CCs). We hypothesize that differences in overall survival (OS) exist between patients undergoing surgery for HPVOPC at CCs and low (<15 TORS/year; LVACs) and high (≥15 TORS/year; HVACS)
-
Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-09 Martina Pagliuca, Julie Havas, Emilie Thomas, Youenn Drouet, Davide Soldato, Maria Alice Franzoi, Joana Ribeiro, Camila K Chiodi, Emma Gillanders, Barbara Pistilli, Gwenn Menvielle, Florence Joly, Florence Lerebours, Olivier Rigal, Thierry Petit, Sylvie Giacchetti, Florence Dalenc, Johanna Wassermann, Olivier Arsene, Anne Laure Martin, Sibille Everhard, Olivier Tredan, Sandrine Boyault, Michelino De
Background Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms (CRBS) that may persist years after early-stage breast cancer (BC), affecting quality of life. We aimed at generating a predictive model of long-term CRBS clusters among BC survivors four years post-diagnosis. Methods Patients with early-stage BC were included from the CANcer
-
Long-Term survival across breslow thickness categories: Findings from a Population-Based study of 210,042 Australian melanoma patients. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-09 Serigne N Lo,Gabrielle J Williams,Anne E Cust,Alexander H R Varey,Sydney Ch'ng Md,Richard A Scolyer,John F Thompson
The prognosis of a patient with a primary cutaneous melanoma is known to be related to the Breslow thickness of their tumor. This study sought to determine long-term (30-year) survival rates for the four AJCC 8th Edition T-categories by analyzing Australian registry data for 210,042 melanoma patients diagnosed from 1982-2014. The 30-year incidence rates of death due to melanoma and non-melanoma causes
-
Racial and socioeconomic disparities in NSCLC molecular diagnostics uptake J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-08 Stephanie Tuminello, Wiley M Turner, Matthew Untalan, Tara Ivic-Pavlicic, Raja Flores, Emanuela Taioli
Background Precision therapies, such as targeted and immunotherapies, have substantially changed the landscape of late-stage non-small cell lung cancer (NSCLC). Yet utilization of these therapies is disproportionate across strata defined by race and socioeconomic status (SES), possibly due to disparities in molecular diagnostic testing (or “biomarker testing”), which is a prerequisite to treatment
-
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-07 Alexander G Goglia, Mohammed Alshalalfa, Anwar Khan, Danielle R Isakov, Helen Y Hougen, Nishwant Swami, Jasmine Kannikal, Sean M Mcbride, Daniel R Gomez, Sanoj Punnen, Paul L Nguyen, Puneeth Iyengar, Emmanuel S Antonarakis, Brandon A Mahal, Edward Christopher Dee
Introduction Alterations in forkhead box A1 (FOXA1), a pioneer transcription factor, are associated with poor prognosis in breast cancer (BC) and prostate cancer (PC). We characterized FOXA1 genomic alterations and their clinical impacts in a large pan-cancer cohort from the AACR GENIE database. Methods FOXA1 alterations were characterized across >87,000 samples from >30 cancer types for primary and
-
CC-Connect: Identifying solutions to elevating the cancer experience for adolescents and young adults (AYA) with cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-07 Michael E Roth, Douglas S Hawkins, Janette K Merrill, Tara O Henderson
Adolescents and young adults with cancer (AYAs, aged 15 to 39 years) experience unique challenges due to their developmental life stage, and many have limited access to support and resources. CC-Connect, the patient assistance component of the White House Cancer Moonshot CC-DIRECT initiative that aims to help childhood cancer families find the best care for their child, undertook a multipronged effort
-
Understanding risk factors for endometrial cancer in young women. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-05 Noah Charles Peeri,Kimberly A Bertrand,Renhua Na,Immaculata De Vivo,Veronica Wendy Setiawan,Venkatraman E Seshan,Laia Alemany,Yu Chen,Megan A Clarke,Tess Clendenen,Linda S Cook,Laura Costas,Luigino Dal Maso,Jo L Freudenheim,Christine M Friedenreich,Gretchen L Gierach,Marc T Goodman,Carlo La Vecchia,Fabio Levi,Marta Lopez-Querol,Lingeng Lu,Kirsten B Moysich,George Mutter,Jeffin Naduparambil,Eva Negri
BACKGROUND The American Cancer Society recommends physicians inform average risk women about endometrial cancer (EC) risk on reaching menopause, but new diagnoses are rising fastest in women <50 years. Educating these women about EC risks requires knowledge of risk factors. However, EC in young women is rare and challenging to study in single study populations. METHODS We included 13,846 incident EC
-
Phase III randomized trial comparing neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-02 Vanita Noronha, Vijay Maruti Patil, Nandini Menon, Amit Joshi, Minit Jalan Shah, Ajaykumar Singh, Supriya Goud, Srushti Shah, Sucheta More, Kavita Nawale, Dipti Nakti, Akanksha Yadav, Shweta Jogdhankar, Rajeev Kumar, Virendra Kumar Tiwari, Devayani Niyogi, Nilendu Purandare, Amit Janu, Nivedita Chakrabarty, Abhishek Mahajan, Anil Tibdewal, Jaiprakash Agarwal, Akash Pawar, Oindrila Roy Chowdhury, Vibhor
Purpose Standard neoadjuvant chemotherapy (NACT) for locally advanced esophageal/gastroesophageal junction squamous cancer (LAEGSC), 5-fluorouracil (5FU)+platinum, is toxic and logistically challenging; alternative regimens are needed. Patients and Methods Phase III randomized open-label non-inferiority trial at Tata Memorial Center, India, in resectable LAEGSC. Patients were randomized 1:1 to three
-
A Comprehensive Analysis of Metastatic Disease following Surgery for Clinically Localized Cutaneous Melanoma J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-02 Christina S Boutros, Hanna Kakish, Omkar S Pawar, Alexander W Loftus, John B Ammori, Jeremy Bordeaux, Ankit Mangla, Iris Sheng, Gary Schwartz, Luke D Rothermel, Richard S Hoehn
Introduction The NCCN considers “baseline staging” (whole body CT or PET scan +/- brain MRI) for all asymptomatic melanoma patients with a positive sentinel lymph node biopsy. The true yield of these workups is unknown. Methods We created cohorts of adult malignant melanoma patients, using the National Cancer Database (2012-2020) to mimic three common scenarios: (1) clinically node negative, with positive
-
RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma? J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-09-01 Jaleh Fallah,Haley Gittleman,Chana Weinstock,Elaine Chang,Sundeep Agrawal,Shenghui Tang,Richard Pazdur,Paul G Kluetz,Daniel L Suzman,Laleh Amiri-Kordestani
-
Correction to: Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-30
-
Accelerating Progress to Reduce the Cancer Burden through Prevention and Control in the US J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-30 Katrina A B Goddard, Eric J Feuer, Asad Umar, Philip E Castle
Improvements in cancer prevention and control are poised to be main contributors in reducing the burden of cancer in the US. We quantify top opportunities to accelerate progress using projected life years gained (LYG) and deaths averted as measures. We project that over the next 25 years, realistic gains from tobacco control can contribute 0.4 to 17 million additional LYG per intervention and 8.4 million
-
Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-29 En Cheng, Fang-Shu Ou, Clare Gatten, Chao Ma, Alan P Venook, Heinz-Josef Lenz, Eileen M O’Reilly, Peter T Campbell, Chaoyuan Kuang, Bette J Caan, Charles D Blanke, Kimmie Ng, Jeffrey A Meyerhardt
Background Plant-based diet is associated with better survival among patients with non-metastatic colorectal cancer (CRC), but its association in metastatic CRC is unknown. Methods Using an NCI-sponsored trial (CALGB/SWOG 80405), we included 1,284 patients who completed validated food frequency questionnaires at the initiation of metastatic CRC treatment. We calculated three indices: overall plant-based
-
Assessment of Intermediate-Term Mortality Following Pancreatectomy for Cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-29 Lauren M Janczewski, Michael R Visenio, Rachel Hae-Soo Joung, Anthony D Yang, David D O’Dell, Elizabeth C Danielson, Mitchell C Posner, Ted A Skolarus, David J Bentrem, Karl Y Bilimoria, Ryan P Merkow
Background Pancreatic cancer remains highly lethal and resection represents the only chance for cure. Although patients are counseled regarding short-term (0-3 months) mortality, little is known about mortality 3-6 months (intermediate-term) following surgery. We assessed predictors of intermediate-term mortality, evaluated hospital-level variation, and developed a nomogram to predict intermediate-term
-
Gerotherapeutics: Aging Mechanism-based Pharmaceutical and Behavioral Interventions to Reduce Cancer Racial and Ethnic Disparities J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-27 Jeanne S Mandelblatt, Michael H Antoni, Traci N Bethea, Steve Cole, Barry I Hudson, Frank J Penedo, Amelie G Ramirez, G William Rebeck, Swarnavo Sarkar, Ann G Schwartz, Erica K Sloan, Yun-Ling Zheng, Judith E Carroll, Mina S Sedrak
The central premise of this article is that a portion of the established relationships between social determinants of health and racial/ethnic disparities in cancer morbidity and mortality are mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions
-
Genetic Risk, Health-Associated Lifestyle, and Risk of Early-onset Total Cancer and Breast Cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-27 Yin Zhang, Sara Lindström, Peter Kraft, Yuxi Liu
Background Early-onset cancer (diagnosed under age 50) generally manifests as an aggressive disease phenotype. The association between healthy lifestyle and early-onset cancer and whether it varies by common genetic variants remains unclear. Methods We analyzed a prospective cohort of 66,308 participants who were under age 50 and free of cancer at baseline in the UK Biobank. Using Cox regression, we
-
Integrative multi-omics characterization of hepatocellular carcinoma in hispanic patients J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-27 Debodipta Das, Xiaojing Wang, Yu-Chiao Chiu, Hakim Bouamar, Francis E Sharkey, Jorge E Lopera, Zhao Lai, Susan T Weintraub, Xianlin Han, Yi Zou, Hung-I H Chen, Carla R Zeballos Torrez, Xiang Gu, Matyas Cserhati, Joel E Michalek, Glenn A Halff, Yidong Chen, Siyuan Zheng, Francisco G Cigarroa, Lu-Zhe Sun
Background The incidence and mortality rates of hepatocellular carcinoma (HCC) among Hispanic individuals in the United States are much higher than in non-Hispanic white people. We conducted multi-omics analyses to elucidate molecular alterations in HCC among Hispanic patients. Methods Paired tumor and adjacent non-tumor samples were collected from 31 Hispanic HCCs in South Texas (STX-Hispanic) for
-
RE: "prevalence of cancer survivors in the United States". J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-24 Jason Domogauer,Marina Stasenko,Gwendolyn P Quinn,Matthew B Schabath
-
Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-24 Justin C Brown, Chao Ma, Qian Shi, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Victor Chang, Richard M Goldberg, Eileen M O'Reilly, Anthony F Shields, Jeffrey A Meyerhardt
Background Both inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown. Methods This cohort study was nested within the CALGB/SWOG 80702 (Alliance) randomized trial. Inflammatory burden was quantified
-
Celebrating the 1945 JNCI pioneering contribution to antiangiogenic therapy for cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-23 Giovanna Tosato,Yuyi Wang
-
Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-22 William D Foulkes,Paz Polak
-
Expanding the list of cancers recognized to be caused by infectious agents. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-22 Gary M Clifford
-
Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-21 Qinran Liu,Heidy N Medina,Tulay Koru-Sengul,Estelamari Rodriguez,Gilberto Lopes,Frank J Penedo,Farhad Islami,Paulo S Pinheiro
BACKGROUND Despite the importance of early detection for lung cancer outcomes, staging disparities among the growing US Hispanic population remain underexplored. This population-based study aimed to identify racial-ethnic disparities among non-Hispanic White, non-Hispanic Black, and Hispanic (including specific subgroups) patients in stage at diagnosis for potentially curable non-small cell lung cancer
-
Academic Readiness among Young Children Treated for Brain Tumors: A Multisite, Prospective, Longitudinal Trial J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-21 Melanie R Somekh, Jason M Ashford, Michelle A Swain, Lana L Harder, Bonnie L Carlson-Green, Joanna Wallace, Ryan J Kaner, Catherine A Billups, Arzu Onar-Thomas, Jeanelle S Ali, Jennifer L Harman, Thomas E Merchant, Amar Gajjar, Heather M Conklin
BACKGROUND Young children treated for central nervous system (CNS) malignancies are at high risk for difficulties with academic functioning due to increased vulnerability of the developing brain and missed early developmental opportunities. Extant literature examining academics in this population is limited. We investigated academic readiness, its clinical and demographic predictors, and its relationship
-
Treatment of Stages I-III Squamous Cell Anal Cancer: A Comparative Effectiveness Systematic Review. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-20 Alexander Troester,Romil Parikh,Bronwyn Southwell,Elizabeth Ester,Shahnaz Sultan,Edward Greeno,Elliot Arsoniadis,Timothy R Church,Timothy Wilt,Mary Butler,Paolo Goffredo
PURPOSE To assess the effectiveness and harms of initial treatment strategies for stages I-III anal squamous cell cancer (SCC). METHODS We searched Medline®, Embase®, and CENTRAL®, between January 1, 2000- March 2024, for randomized controlled trials and nonrandomized studies of interventions comparing initial treatment strategies. Individual study risk of bias (RoB) and overall strength of evidence
-
A Validated Estimate of Visceral Adipose Tissue Volume in Relation to Cancer Risk J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-14 Yujia Lu, Yu Chen Zhao, Kuangyu Liu, Alaina Bever, Ziyi Zhou, Kai Wang, Zhe Fang, Georgios Polychronidis, Yuchen Liu, Liyuan Tao, Barbra A Dickerman, Edward L Giovannucci, Mingyang Song
Background Despite the recognized role of visceral adipose tissue (VAT) in carcinogenesis, its independent association with cancer risk beyond traditional obesity measures remains unknown due to limited availability of imaging data. Methods We developed an estimation equation for VAT volume (L) using Elastic Net Regression based on demographic and anthropometric data in a subcohort of participants
-
Deciphering the Sex gap in global life expectancy: the impact of female-specific cancers 1990–2019 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-14 Sergi Trias-Llimós, Elisenda Rentería, Roberta Rutigliano, Ajay Aggarwal, Jennifer Moodley, Karla Unger-Saldaña, Isabelle Soerjomataram
Background Females live longer than males, which results in a sex gap in life expectancy. This study examines the contribution of female cancers to this differential by world region and country 1990-2019 with special focus to the 15-69 age group. Methods Cause-specific mortality data for 30 cancers, including four female-specific cancers from 238 countries and territories was retrieved from the Global
-
Reducing ovarian cancer mortality through screening: an impossible dream? J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-12 Evan R Myers
-
Uptake of Breast Cancer Screening Practices in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-10 Reza Ebrahimoghli, Mir Hossein Aghaei, Saber Azami-Aghdash, Nehmat Houssami
Background Breast cancer is the most prevalent cancer worldwide and the leading cause of cancer mortality in women. Uptake of breast cancer screening and early-detection practices in low- and middle-income countries (LMICs) has not been synthesized. We aimed to systematically quantify uptake of breast cancer screening in LMICs. Methods We performed a systematic review and meta-analysis of observational
-
Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-09 Julia Foldi, Neil Carleton, Stewart J Anderson, Priya Rastogi, Adrian Lee, Marija Balic, Charles E Geyer, Steffi Oesterreich, Norman Wolmark
We evaluated differences in long-term outcomes of invasive lobular carcinoma (ILC) vs breast cancers of no special type (NST) treated with anthracycline-based adjuvant chemotherapy using 4 National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized phase III trials (B-22, B-25, B-28, B-30). Our cohort included 11,251 patients with NST and 1,231 with ILC. Patients with ILC were older, had
-
Exercise and nutrition to improve cancer Treatment-Related outcomes (ENICTO). J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-08 Kathryn H Schmitz,Justin C Brown,Melinda L Irwin,Kim Robien,Jessica M Scott,Nathan A Berger,Bette Caan,Andrea Cercek,Tracy E Crane,Scott R Evans,Jennifer A Ligibel,Jeffrey A Meyerhardt,Tanya Agurs-Collins,Karen Basen-Engquist,Jennifer W Bea,Sheng F Cai,Brenda Cartmel,Vernon M Chinchilli,Wendy Demark-Wahnefried,Christina M Dieli-Conwright,Loretta DiPietro,Shawna E Doerksen,Sharon L Edelstein,Joanne
Chemotherapy treatment-related side-effects are common and increase the risk of suboptimal outcomes. Exercise interventions during cancer treatment improve self-reported physical functioning, fatigue, anxiety, and depression, but it is unclear whether these interventions improve important clinical outcomes, such as chemotherapy relative dose intensity (RDI). The National Cancer Institute funded the
-
Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-08 Peter S Liang,Divya Bhatt
-
Ambient ultraviolet A, ultraviolet B and risk of melanoma in a nationwide United States cohort, 1984-2014 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-08 Elizabeth K Cahoon, Soutrik Mandal, Ruth M Pfeiffer, David C Wheeler, Michael R Sargen, Bruce H Alexander, Cari M Kitahara, Martha S Linet, Jim Z Mai
Background Ultraviolet radiation (UVR) exposure is the primary risk factor for melanoma although the relationship is complex. Compared to radiation from UVB wavelengths, UVA makes up a majority of the surface solar UVR, penetrates the skin more deeply, is the principal range emitted by tanning beds, and is less filtered by sunscreens and window glass. Few studies have examined the relationship between
-
Physical Activity and Cognition: Longitudinal findings from the Thinking and Living with Cancer Study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-07 Ashley L Artese, Xingtao Zhou, Danielle B Tometich, Brent J Small, Tim A Ahles, Jaeil Ahn, Traci N Bethea, Elizabeth C Breen, Harvey J Cohen, Martine Extermann, Deena Graham, Claudine Isaacs, Heather S L Jim, Brenna C McDonald, Zev M Nakamura, Sunita K Patel, Kelly E Rentscher, James C Root, Andrew J Saykin, Kathleen Van Dyk, Wanting Zhai, Judith E Carroll, Jeanne Mandelblatt
Background Physical activity can improve cognition; however, little is known regarding the relationships between longitudinal objectively-measured physical activity, cognition, and inflammation in older breast cancer survivors. Methods Older (≥60 yrs) breast cancer survivors (n = 216) and frequency-matched non-cancer controls (n = 216) were assessed at baseline (pre-systemic therapy for survivors)
-
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-07 Davide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, Sara Gandini, Gunnar Mellgren, Parijatham Thomas, Katherine D Crew, Nagi B Kumar, Debora Macis, Valentina Aristarco, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Mauro D’Amico, Tania Buttiron-Webber, Irene Maria Briata, Stefano Spinaci, Viviana Galimberti, Lana A Vornik, Eduardo Villar-Sanchez, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo
The drug's activity at the target tissue could help to define the minimal effective dose to promote cancer preventive therapy. Here we present exemestane and sex hormone concentrations within breast tissue from a pre-surgical study of alternative exemestane schedules. Postmenopausal women candidate for breast surgery for estrogen receptor-positive breast cancer were randomized to exemestane 25 mg once
-
-
-
-
-
When the somatic genome informs the germline: the example of TP53. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Payal P Khincha,Sharon A Savage
-
Dietary interventions, statistical power, and unanswered questions. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Calvin Smith,Christopher M Booth,Ghulam Rehman Mohyuddin
-
Time to change the paradigm for primary endpoints in cancer screening trials? J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Talía Malagón
-
RE: The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Bareera Shamsi,Mariam Hina,Sarah Akhtar,Fabiha Shakeel,Bilal Ahmed,Sehrish Abrar,Asim Hafiz,Bilal Mazhar Qureshi,Nasir Ali,Ahmed Nadeem Abbasi
-
Response to Shamsi, Hina, Akhtar, et al. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Ryan S Huang,Srinivas Raman
-
Prediagnostic plasma proteomics profile for hepatocellular carcinoma. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Xinyuan Zhang,Longgang Zhao,Long H Ngo,Simon T Dillon,Xuesong Gu,Michelle Lai,Tracey G Simon,Andrew T Chan,Edward L Giovannucci,Towia A Libermann,Xuehong Zhang
OBJECTIVE Proteomics may discover pathophysiological changes related to hepatocellular carcinoma, an aggressive and lethal type of cancer with low sensitivity for early stage diagnosis. DESIGN We measured 1305 prediagnostic (median = 12.7 years) SomaScan proteins from 54 pairs of healthy individuals who subsequently developed hepatocellular carcinoma and matched non-hepatocellular carcinoma control
-
Adolescents and young adults with cancer: the clinical course of COVID-19 infections. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Julie A Wolfson,Elizabeth S Davis,Aniket Saha,Isaac Martinez,David McCall,Prachi Kothari,Julienne Brackett,David S Dickens,Alissa R Kahn,Carla Schwalm,Archana Sharma,Joshua Richman,Branko Cuglievan,,Smita Bhatia,Chen Dai,Jennifer M Levine,Emily E Johnston
Adolescents and young adults (ie, individuals aged 15-39 years, known as AYAs) with cancer face unique vulnerabilities yet remain underrepresented in clinical trials, including adult registries of COVID-19 in cancer (AYAs: 8%-12%). We used the Pediatric Oncology COVID-19 Case Report to examine the clinical course of COVID-19 among AYAs with cancer. The Pediatric Oncology COVID-19 Case Report collects
-
TP53-associated early breast cancer: new observations from a large cohort. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Renata L Sandoval,Michele Bottosso,Li Tianyu,Natalia Polidorio,Brittany L Bychkovsky,Benjamin Verret,Alessandra Gennari,Sophie Cahill,Maria Isabel Achatz,Olivier Caron,Marion Imbert-Bouteille,Catherine Noguès,Kara N Mawell,Cristina Fortuno,Amanda B Spurdle,Nabihah Tayob,Fabrice Andre,Judy E Garber
BACKGROUND A recent large, well-annotated international cohort of patients with Li-Fraumeni syndrome and early-stage breast cancer was examined for shared features. METHODS This multicenter cohort study included women with a germline TP53 pathogenic or likely pathogenic variant and nonmetastatic breast cancer diagnosed between 2002 and 2022. Clinical and genetic data were obtained from institutional
-
Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-08-01 Casper W F van Eijck,Disha Vadgama,Casper H J van Eijck,Johanna W Wilmink,
BACKGROUND Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant exploration in treating pancreatic cancer. This study aimed to investigate the influence of metformin on patient survival and its potential correlation with distinct immune profiles in pancreatic ductal adenocarcinoma (PDAC) tumors. METHODS We included 82 upfront